Key points• Nitric oxide (NO) is an important vasodilatory signalling molecule that regulates O 2 pressure within the skeletal muscle microvasculature (P O 2 mv ). In healthy subjects, NO is derived from two principal NO synthase (NOS) isoforms: neuronal NOS (nNOS) and endothelial NOS (eNOS).• Chronic heart failure (CHF) results in peripheral vascular dysfunction that is attributed, in part, to impaired NO function. This NO-mediated impairment is attributed generally to eNOS dysfunction. It is unknown if nNOS-mediated regulation of P O 2 mv function is impaired in CHF.• Our present results demonstrate that skeletal muscle blood flow reductions and P O 2 mv alterations during contractions observed following nNOS inhibition in healthy rats are markedly attenuated or absent in CHF rats, which is indicative of impaired nNOS function.• Identification of the mechanisms underlying impaired microvascular function in CHF is an important step in the development of treatments designed to improve CHF-induced skeletal muscle microvascular pathology.Abstract Chronic heart failure (CHF) impairs nitric oxide (NO)-mediated regulation of the skeletal muscle microvascular O 2 delivery/V O 2 ratio (which sets the microvascular O 2 pressure, P O 2 mv ). Given the pervasiveness of endothelial dysfunction in CHF, this NO-mediated dysregulation is attributed generally to eNOS. It is unknown whether nNOS-mediated P O 2 mv regulation is altered in CHF. We tested the hypothesis that CHF impairs nNOS-mediated P O 2 mv control. In healthy and CHF (left ventricular end diastolic pressure (LVEDP): 6 ± 1 versus 14 ± 1 mmHg, respectively, P < 0.05) rats spinotrapezius muscle blood flow (radiolabelled microspheres), P O 2 mv (phosphorescence quenching), andV O 2 (Fick calculation) were measured before and after 0.56 mg kg −1 I.A. of the selective nNOS inhibitor S-methyl-L-thiocitrulline (SMTC). In healthy rats, SMTC increased baseline P O 2 mv (Control: 29.7 ± 1.4, SMTC: 34.4 ± 1.9 mmHg, P < 0.05) by reducingV O 2 (↓20%) without any effect on blood flow and speeded the mean response time (MRT, time to reach 63% of the overall kinetics response, Control: 24.2 ± 2.0, SMTC: 18.5 ± 1.3 s, P < 0.05). In CHF rats, SMTC did not alter baseline P O 2 mv (Control: 25.7 ± 1.6, SMTC: 28.6 ± 2.1 mmHg, P > 0.05),V O 2 at rest, or the MRT (Control: 22.8 ± 2.6, SMTC: 21.3 ± 3.0 s, P > 0.05). During the contracting steady-state, SMTC reduced blood flow (↓15%) andV O 2 (↓15%) in healthy rats such that P O 2 mv was unaltered (Control: 19.8 ± 1.7, SMTC: 20.7 ± 1.8 mmHg, P > 0.05). In marked contrast, in CHF rats SMTC did not change contracting steady-state blood flow,V O 2 , or P O 2 mv (Control: 17.0 ± 1.4, SMTC: 17.7 ± 1.8 mmHg, P > 0.05). nNOS-mediated control of skeletal muscle microvascular function is compromised in CHF versus C 2012 The Authors. Abbreviations: ACh, acetylcholine; CHF, chronic heart failure; eNOS, endothelial nitric oxide synthase; HR, heart rate; iNOS, inducible nitric oxide synthase; LV, left ventricle; LV dp/dt, left ventricular change in ...